Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients - Takeaways - MDSpire

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients

  • By

  • Huan Xie

  • Maoyuan Xiang

  • Meijuan Zhang

  • Fanqiao Meng

  • Yan Qi

  • Kehong Chen

  • Dongfeng Zeng

  • June 23, 2026

  • 0 min

Share

  • 1

    The study evaluated the safety and efficacy of a lower-dose daratumumab regimen combined with bortezomib and dexamethasone in newly diagnosed MGRS patients.

  • 2

    Ten patients participated in the open-label, single-arm clinical trial, receiving six cycles of the DVd-lite treatment protocol.

  • 3

    The hematological overall response rate (ORR) was 80%, while the renal ORR reached 90%, with complete response rates of 60% in both categories.

  • 4

    Only one patient experienced a grade 3 treatment-related adverse event during the study, indicating a favorable safety profile.

  • 5

    The findings suggest that the DVd-lite regimen may serve as a potent initial therapeutic option for patients with newly diagnosed MGRS.

Original Source(s)

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients

  • by Huan Xie, Maoyuan Xiang, Meijuan Zhang, Fanqiao Meng, Yan Qi, Kehong Chen, Dongfeng Zeng

  • June 23, 2026

Related Content

Immune heterogeneity and therapeutic resistance in gynecological malignancies

Integrated therapy including acupuncture in a patient with long-term survival from spinal cord metastases of ALK-positive lung adenocarcinoma: a case report

Palliative Care Coaching for Family Caregivers of Patients With Advanced Cancer: A Randomized Clinical Trial